Literature DB >> 32265192

Circulating Retinol-Binding Protein 4 Is Inversely Associated With Pancreatic β-Cell Function Across the Spectrum of Glycemia.

Rong Huang1,2, Songping Yin1,2, Yongxin Ye1,2, Nixuan Chen1,2, Shiyun Luo1,2, Min Xia3,2, Lina Zhao3,2.   

Abstract

OBJECTIVE: The aim of this study was to examine the association of circulating retinol-binding protein 4 (RBP4) levels with β-cell function across the spectrum of glucose tolerance from normal to overt type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 291 subjects aged 35-60 years with normal glucose tolerance (NGT), newly diagnosed impaired fasting glucose or glucose tolerance (IFG/IGT), or type 2 diabetes were screened by a standard 2-h oral glucose tolerance test (OGTT) with the use of traditional measures to evaluate β-cell function. From these participants, 74 subjects were recruited for an oral minimal model test, and β-cell function was assessed with model-derived indices. Circulating RBP4 levels were measured by a commercially available ELISA kit.
RESULTS: Circulating RBP4 levels were significantly and inversely correlated with β-cell function indicated by the Stumvoll first-phase and second-phase insulin secretion indices, but not with HOMA of β-cell function, calculated from the 2-h OGTT in 291 subjects across the spectrum of glycemia. The inverse association was also observed in subjects involved in the oral minimal model test with β-cell function assessed by both direct measures and model-derived measures, after adjustment for potential confounders. Moreover, RBP4 emerged as an independent factor of the disposition index-total insulin secretion.
CONCLUSIONS: Circulating RBP4 levels are inversely and independently correlated with β-cell function across the spectrum of glycemia, providing another possible explanation of the linkage between RBP4 and the pathogenesis of type 2 diabetes.
© 2020 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32265192     DOI: 10.2337/dc19-2432

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

1.  Comparative Evaluation of Chiglitazar and Sitagliptin on the Levels of Retinol-Binding Protein 4 and Its Correlation With Insulin Resistance in Patients With Type 2 Diabetes.

Authors:  Yunting Zhou; Huiying Wang; Yuming Wang; Xiaohua Xu; Fengfei Li; Junming Zhou; Ting Shan; Rong Huang; Tingting Cai; Xiaomei Liu; Xiaofei Su; Huiqin Li; Jianhua Ma
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-25       Impact factor: 6.055

2.  Sexual Dimorphism in the Association of Serum Retinol-Binding Protein-4 With Long-Term Dynamic Metabolic Profiles in Non-Diabetes.

Authors:  Jiali Xiang; Huajie Dai; Yanan Hou; Qi Wang; Tiange Wang; Mian Li; Zhiyun Zhao; Jieli Lu; Meng Dai; Di Zhang; Yu Xu; Guang Ning; Weiqing Wang; Jiqiu Wang; Yufang Bi; Min Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-11       Impact factor: 6.055

3.  Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes.

Authors:  Xu Liu; Yang Liu; Hongzhong Liu; Haiyan Li; Jianhong Yang; Pei Hu; Xinhua Xiao; Dongyang Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-20       Impact factor: 5.555

Review 4.  Interplay between Fatty Acid Binding Protein 4, Fetuin-A, Retinol Binding Protein 4 and Thyroid Function in Metabolic Dysregulation.

Authors:  Daniela Dadej; Ewelina Szczepanek-Parulska; Marek Ruchała
Journal:  Metabolites       Date:  2022-03-29

5.  The adipocyte-enriched secretory protein tetranectin exacerbates type 2 diabetes by inhibiting insulin secretion from β cells.

Authors:  Fen Liu; Zixin Cai; Yan Yang; George Plasko; Piao Zhao; Xiangyue Wu; Cheng Tang; Dandan Li; Ting Li; Shanbiao Hu; Lei Song; Shaojie Yu; Ran Xu; Hairong Luo; Libin Fan; Ersong Wang; Zhen Xiao; Yujiao Ji; Rong Zeng; Rongxia Li; Juli Bai; Zhiguang Zhou; Feng Liu; Jingjing Zhang
Journal:  Sci Adv       Date:  2022-09-21       Impact factor: 14.957

6.  Augmentation of RBP4/STRA6 signaling leads to insulin resistance and inflammation and the plausible therapeutic role of vildagliptin and metformin.

Authors:  Kuppan Gokulakrishnan; Gautam Kumar Pandey; Chandrakumar Sathishkumar; Saravanakumar Sundararajan; Prabhu Durairaj; Nagaraj Manickam; Viswanathan Mohan; Muthuswamy Balasubramanyam
Journal:  Mol Biol Rep       Date:  2021-05-26       Impact factor: 2.316

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.